Sable Offshore (NYSE:SOC) Bolsa

SABLE OFFSHORE CORP

Sable Offshore

Sable Offshore Corp is a Houston-based independent upstream company focused on responsibly developing the prolific Santa Ynez Unit in federal waters offshore California. The company is managed as one reportable segment, oil and gas.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

ABTS

DEVS

GIBO

IXHL

MTUS

NVVE

Next Technology Holding Inc. - Ordinary Shares

NXTT

OLMA

RSLS

RYDE

SHPH

SISI

SYTA

TAOP

Las acciones de Sable Offshore suben un 12,6 % en la preapertura tras publicar resultados del primer trimestre.

Las acciones de Sable Offshore (SOC) suben un 13%; Aquí están 20 acciones que se mueven en premercado

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANAB

ASST

CCLD

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DWTX

HSDT

HUBC

LSTA

NEHC

NFLX

SEPN

STFS

USEG

Netflix sorprende con un aumento en suscriptores y mejores pronósticos. Descubre también los mayores ganadores y perdedores del premercado.

Acciones de Netflix se disparan alrededor del 15%; 20 acciones que se están moviendo en el premercado de EE.UU.

Long Ideas

Small Cap

Te presentamos 2 acciones de energía que se encuentran sobrevendidas, con un RSI cercano o por debajo de 30.

2 acciones de energía que podrían aumentar en abril

Sable Offshore Corp

Soda Coin

SOCFINASIA SA HOLDING by Socfinasia SA Holding

Socfinasia SA Holding

STHN CAL GAS 6 PR by Southern California Gas Co.

Southern California Gas Co

STHN CAL GAS 6 A PR by Southern California Gas Co.

Unisocks

Global X Social Media ETF

Pharos Energy PLC

Socionext Inc

Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#CSE">QNTM</a>) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD $1,000,000 worth of Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. This brings the total amount of BTC and other cryptocurrencies purchased to USD $4,500,000. As previously announced the company will continue to allow for future financing and other transactions to be carried out in cryptocurrency.

CSE:QNTM

QNTM

Quantum Biopharma Purchases Additional $1M Worth Of Bitcoin And Other Cryptocurrencies As Part Of Strategic Efforts, Bringing Total Investment In Digital Assets To $4.5M

Citigroup analyst Scott Gruber downgrades Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) from Buy to Neutral and lowers the price target from $25 to $19.

Downgrades

Price Target

Analyst Ratings

Citigroup Downgrades Helmerich & Payne to Neutral, Lowers Price Target to $19

HC Wainwright &amp; Co. analyst Robert Burns maintains Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Buy and lowers the price target from $12 to $11.

YMAB

HC Wainwright & Co. Maintains Buy on Y-mAbs Therapeutics, Lowers Price Target to $11

U.S. President Donald Trump has demanded a comprehensive investigation into the celebrity endorsements received by Kamala Harris during the 2024 election. He alleges that these endorsements involved illegal compensation.
What Happened:&nbsp;Trump took to his Truth Social early Monday and singled out celebrities like Bruce Springsteen, Beyoncé, Oprah Winfrey and Bono, who publicly backed Harris.&nbsp;He made claims that these endorsements were bought, which he believes is against the law.
Trump accused Harris of disguising payments for entertainment as compensation for these celebrity endorsements. He went on to label the artists who supported Harris as &#8220;unpatriotic.&#8221;
Harris&#8217; Office did not immediately respond to Benzinga&#8217;s request for comment. 
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="610" height="473" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19063509/image-225.png" alt="" class="wp-image-919578" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19063509/image-225.png 610w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/19063509/image-225-300x233.png 300w" sizes="(max-width: 610px) 100vw, 610px" /></figure>
However, Politico reported that these allegations have been refuted by Beyoncé&#8217;s mother and Winfrey, who insisted that the artists did not receive any personal fees for their endorsements. Campaign finance records indicate that Harris&#8217; campaign paid $165,000 to Beyoncé&#8217;s production company and&nbsp;$1 million was paid to Winfrey&#8217;s company, Harpo Productions.
Despite raising over&nbsp;$1 billion in just a&nbsp;few months, the Harris campaign has been subject to rumors of paying millions to celebrities for their support. These rumors have been categorically denied by the celebrities&#8217; teams.
SEE ALSO: <a href="https://benzinga.com/news/global/25/05/45487501/trump-pushes-for-russia-ukraine-ceasefire-to-end-bloodbath-in-high-stakes-calls-with-russian-president-and-zelenskyy-amid-drone-attacks" target="_blank" rel="noreferrer noopener">Trump Pushes For Russia-Ukraine Ceasefire To End &#8216;Bloodbath&#8217; In High-Stakes Calls With Russian President And Zelenskyy Amid Drone Attacks</a>
Why It Matters: Trump lashed out at Bruce Springsteen last week, calling him "not a talented guy" and criticizing his appearance, after the musician labeled the Trump administration "corrupt, incompetent and treasonous" during a concert in England.
Notably, the 2024 election saw a significant increase in celebrity involvement in politics. Following Trump&#8217;s second victory, several high-profile celebrity Americans announced plans to <a href="https://www.benzinga.com/real-estate/24/11/41982378/trumps-win-has-celebrities-saying-goodbye-america-see-where-theyre-going">relocate </a>abroad in November 2024.
Moreover, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk actively <a href="https://www.benzinga.com/news/24/10/41561298/elon-musk-pumps-more-than-130m-into-trump-and-gop-campaigns">campaigned </a>for Trump, investing over $130 million in Trump and GOP campaigns. Meanwhile, Politico reported that Trump has actively sought celebrity endorsements in all three of his presidential campaigns, including from figures like Kanye West and Kid Rock, who even appeared at key events like the Republican National Convention and his inauguration-eve rally.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/05/45486040/chuck-schumer-raises-concerns-over-trump-and-doge-impact-on-us-coast-guard-after-mexican-ship-collides-with-brook" target="_blank" rel="noreferrer noopener">Chuck Schumer Raises Concerns Over Trump And DOGE Impact On US Coast Guard After Mexican Ship Collides With Brooklyn Bridge: &#8216;We Know They&#8217;ve Been Meddling&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

TSLA

Did Kamala Harris Pay For Endorsements From Beyoncé, Springsteen, Oprah Winfrey? Trump Demands 'Major Investigation'

Transformational Acquisition Increases Sanmina's Scale and End-Market Exposure to Cloud and AI Infrastructure
Planned Divestiture by AMD Creates Preferred NPI Manufacturing Partnership with Sanmina, a Leading IMS Company
Purchase Price of $2.55 Billion Cash and Equity, Plus $450 Million in Contingent Consideration, Totaling Up to $3 Billion
Transaction Expected to be Accretive to Non-GAAP EPS in First Year Post-Close
Sanmina to Host Conference Call Today at 8:30 a.m. ET (5:30 a.m. PT)
SAN JOSE, Calif., May 19, 2025 /PRNewswire/ -- Sanmina Corporation ("Sanmina") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>), a leading integrated manufacturing solutions company, today announced that it has entered into a definitive agreement to acquire the data center infrastructure manufacturing business of ZT Systems, a leading provider of Cloud and AI infrastructure to the world's largest hyperscalers, from AMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>). The strategic acquisition further establishes Sanmina's position as an industry-leading, vertically integrated global manufacturing solutions provider that can now also accelerate its customers' at scale deployments of cutting-edge AI systems for the data center.
As a combined company, Sanmina expects to strengthen its leading end-to-end component technology, systems integration and supply chain solutions to deliver even greater value for its customers. ZT Systems' current annual net revenue run-rate is approximately $5 - $6 billion and the outlook ahead is promising as new accelerated compute platforms are launched. In addition, ZT Systems' manufacturing team brings over 30 years of systems integration experience and has evolved into a leading provider of high-performance Cloud and AI infrastructure for hyperscalers. The company's advanced liquid cooling capabilities and manufacturing facilities in New Jersey, Texas and the Netherlands, together with its global supply chain, position it to offer end-to-end systems integration, from components to complete racks, for the Cloud and AI infrastructure ecosystem.

SANM

Sanmina To Acquire Data Center Infrastructure Manufacturing Business Of ZT Systems From AMD In $3B Deal; Transaction Expected To Be Accretive To Non-GAAP EPS In First Year Post-Close

Citigroup analyst Scott Gruber downgrades Patterson-UTI Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTEN#NASDAQ">PTEN</a>) from Buy to Neutral and announces $6.5 price target.

PTEN

Citigroup Downgrades Patterson-UTI Energy to Neutral, Announces $6.5 Price Target

HC Wainwright &amp; Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) with a Buy and maintains $4 price target.

Reiteration

VANI

HC Wainwright & Co. Reiterates Buy on Vivani Medical, Maintains $4 Price Target

Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, AUD and alcohol liver disease (ALD). IMPACT, a Phase 2b trial of pemvidutide in MASH, is expected to read out topline data in the second quarter of 2025, and a Phase 2 trial of pemvidutide in ALD is expected to initiate enrollment in the third quarter of 2025.
RECLAIM is a randomized, placebo-controlled trial being conducted at approximately 15 sites in the United States, with Dr. Henry Kranzler, Karl E. Rickels Professor of Psychiatry and Director, Center for Studies of Addiction at the University of Pennsylvania Perelman School of Medicine, serving as the Principal Investigator. The trial is expected to enroll approximately 100 subjects randomized 1:1 to receive either 2.4 mg pemvidutide or placebo weekly for 24 weeks. The primary endpoint of the trial is a change in alcohol consumption, assessed as the change from baseline in the average number of heavy drinking days per week at Week 24, with the key secondary endpoints including the proportion of subjects achieving a 2-level reduction in World Health Organization (WHO) risk drinking level and the absolute change from baseline in average levels of phosphatidylethanol (PEth), a serum biomarker of alcohol intake. An investigational new drug (IND) application for pemvidutide in AUD was filed in December 2024 and was cleared by FDA in January 2025.

Altimmune Begins Phase 2 Trial of Pemvidutide for Alcohol Use Disorder With First Patient Enrolled

Macro Economic Events

Economics

Federal Reserve

Bostic Says Number Of Rate Cuts This Year Depends On How Things Turn Out, Details Of Tariffs Will Matter; Leaning More Towards Only One Cut This Year Because It Will Take Time To Understand Tariffs

Loop Capital analyst Alan Gould upgrades Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) from Hold to Buy and raises the price target from $430 to $510.

Upgrades

CHTR

Loop Capital Upgrades Charter Communications to Buy, Raises Price Target to $510

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) with a Buy and maintains $3.5 price target.

ASRT

HC Wainwright & Co. Reiterates Buy on Assertio Holdings, Maintains $3.5 Price Target

Qualcomm Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) revealed its intentions to manufacture custom data center CPUs, utilizing technology from&nbsp;Nvidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) for connection to Nvidia&#8217;s AI chips.
What Happened: Qualcomm&#8217;s future chips will incorporate Nvidia&#8217;s technology, facilitating rapid communication with Nvidia&#8217;s graphics processors (GPUs), a vital part of its AI chip portfolio. This development signifies Qualcomm&#8217;s re-entry into the data center CPU market, a space typically ruled by Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), said the company on Monday at a presentation at Computex in Taipei, Taiwan, reported Reuters.
Previously, Qualcomm had begun developing an Arm-based (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) CPU in partnership with Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), but had to stop due to cost reductions and legal obstacles. However, after bringing on board a team of former Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) chip designers in 2021, Qualcomm has quietly revived its efforts and is once again in talks with Meta regarding a data center CPU.
Qualcomm recently confirmed a partnership with Saudi AI firm Humain to develop a custom data center CPU. "With the ability to connect our custom processors to Nvidia&#8217;s rack-scale architecture, we&#8217;re advancing a shared vision of high-performance energy-efficient computing to the data center," said CEO Cristiano Amon.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45486943/arthur-hayes-forecasts-bitcoin-will-hit-200000-in-next-bull-run-anticipates-revival-of-fortunes-for-this-hated-coin" target="_blank" rel="noreferrer noopener">Arthur Hayes Forecasts Bitcoin Will Hit $200,000 In Next Bull Run, Anticipates Revival Of Fortunes For This &#8216;Hated&#8217; Coin &#8211; Benzinga</a>
Why It Matters: &nbsp;This move comes as part of Qualcomm&#8217;s broader strategy to diversify its revenue streams. Qualcomm aims to <a href="https://www.benzinga.com/news/earnings/25/05/45127498/qualcomm-plans-22-billion-in-non-handset-revenue-by-2029-with-ai-as-its-trojan-horse">generate </a>$22 billion in non-handset revenue by 2029, with AI being a key driver. The collaboration with Nvidia and the development of custom data center CPUs align with this goal. 
Moreover, association with Nvidia's infrastructure is crucial for any company aiming to break into the data center market, given the central role the Jensen Huang-led company&#8217;s semiconductors play in AI. 
Despite delivering Q2 results that <a href="https://www.benzinga.com/news/25/05/45198245/qualcomm-qcom-shares-dip-despite-q2-earnings-beat-whats-going-on">surpassed </a>Wall Street predictions, Qualcomm&#8217;s shares have dipped 4.6% over the past week. The company&#8217;s foray into the data center CPU&nbsp;market could potentially bolster its performance in the stock market.
Qualcomm holds a momentum rating of 28.77% and a growth rating of 59.61%, according to&nbsp;<a href="https://www.benzinga.com/quote/QCOM" target="_blank" rel="noreferrer noopener">Benzinga's Proprietary Edge Rankings</a>. The Benzinga Growth metric evaluates a stock&#8217;s historical earnings and revenue expansion across multiple timeframes, prioritizing both long-term trends and recent performance.
Over the past month, the shares of Qualcomm Inc. surged 12.02%. 
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/equities/25/05/45486452/jim-cramer-recalls-2011s-6-7-market-decline-after-us-debt-downgrade-says-it-ultimately-meant-not" target="_blank" rel="noreferrer noopener">Jim Cramer Recalls 2011&#8217;s 6.7% Market Decline After US Debt Downgrade, Says It &#8216;Ultimately Meant Nothing:&#8217; Dan Niles Sees Limited Downside Amid Tariff Rollbacks, FOMO</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

AAPL

INTC

NVDA

QCOM

Qualcomm Re-Enters Data Center CPU Market, Taps Nvidia Tech To Power AI Ambitions

Barclays analyst Seth Sigman upgrades Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) from Underweight to Equal-Weight and raises the price target from $131 to $166.

Barclays Upgrades Williams-Sonoma to Equal-Weight, Raises Price Target to $166

HC Wainwright &amp; Co. analyst Andrew Fein maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and raises the price target from $27 to $32.

ACAD

HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $32

Barclays analyst Eddie Kim downgrades Nabors Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBR#NYSE">NBR</a>) from Equal-Weight to Underweight and lowers the price target from $53 to $28.

Barclays Downgrades Nabors Industries to Underweight, Lowers Price Target to $28

Barclays analyst Benjamin Theurer downgrades BRF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRFS#NYSE">BRFS</a>) from Overweight to Equal-Weight and lowers the price target from $5 to $3.5.

BRFS

Barclays Downgrades BRF to Equal-Weight, Lowers Price Target to $3.5

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) with a Buy and maintains $8 price target.

GANX

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

Fed's Bostic Says Moody's Downgrade Will Have Implications For Cost Of Capital, Could Ripple Through Economy; Also Says It Is Unclear If Consumers Can Take On Full Cost Of Tariffs Given State Of Household Balance Sheets And Recent Inflation

JP Morgan analyst Doug Anmuth downgrades Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Overweight to Neutral and raises the price target from $1150 to $1220.

JP Morgan Downgrades Netflix to Neutral, Raises Price Target to $1220

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fluor.com%2F&amp;esheet=54256315&amp;newsitemid=20250519864245&amp;lan=en-US&amp;anchor=Fluor+Corporation&amp;index=1&amp;md5=e7e9a1d9adb37b80a5108bff2f79f317">Fluor Corporation</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) announced today that Bayer's Cell Therapy Launch Facility in Berkeley, California, has been designated the first industrial manufacturing facility in the Western United States to achieve Leadership in Energy and Environmental Design (LEED) v4 Platinum Certification. The project was also named the 2025 Facility of the Year for Social Impact - Unmet Medical Needs by the International Society for Pharmaceutical Engineering (ISPE).
&nbsp;
Bayer's Cell Therapy Launch Facility in Berkeley, California.
LEED v4 Platinum certification is the highest level of recognition for sustainable building practices and indicates that a building meets the highest standards for sustainability.
Fluor's scope of work included the engineering, procurement, construction management, commissioning, qualification and validation for the 144,000-square-foot, state-of-the-art facility. It features 30,000 square feet of cleanroom space dedicated to advancing cell therapy production for neurological degenerative disorders, cardiovascular disease and other unmet medical needs.
"Fluor and Bayer collaborated to deliver Bayer's first fully electric pharmaceutical manufacturing plant, and we met an aggressive schedule to support client and patient needs," said Richard Meserole, President of Fluor's Advanced Technologies &amp; Life Sciences business. "Fluor secured LEED v4 Platinum Certification and ISPE Facility of the Year designation through effective collaboration with our trade partners, lean construction methods, and dedication to quality."
Sustainability benefits for the facility include 52.6% energy cost savings via LED, high-efficiency lighting, heat pump and rooftop solar installation. The facility boasts 100% process water reduction, 98% onsite management of rainfall high efficiency plumbing fixtures, 65% recycled content installation, high use of sustainable materials, land use maximization and various innovation credits.
This is the second new facility built by Fluor on Bayer's Biotech campus in Berkeley. Previously, Fluor completed construction of Bayer's state-of-the-art Single Use Technology biopharmaceutical manufacturing Cell Culture Technology Center in 2021.

Fluor-Built Bayer Facility Becomes First in Western US to Earn LEED v4 Platinum for Sustainability

Press Releases

Sable Offshore Corp. Announces $150 Million Private Placement of Shares and Update on Warrant Exercises

Sable Offshore Corp. Announces Redemption of Public Warrants

Sable Offshore Corp. Provides Update on Pacific Pipeline Company Operations

Sable Offshore Corp. Announces Completion of Redemption of Public Warrants

Sable Offshore Corp. Reports Third Quarter 2024 Financial and Operational Results

Sable Offshore Corp. Continues to Coordinate with California Coastal Commission on Maintenance and Repair Work in the Coastal Zone

Sable Offshore Corp. Provides Update on Litigation Status

Sable Offshore Corp. Reports 2024 Financial and Operational Results

Sable Offshore Corp. Reports First Quarter 2025 Financial and Operational Results

Sable Offshore Corp. Reports Restart of Oil Production at the Santa Ynez Unit and Anticipated Oil Sales from the Las Flores Pipeline System in July 2025

Black Stone Minerals, L.P. Common units representing limited partner interests

Black Stone Minerals

Civitas Resources

CNX Resources

California Resources Corporation Common Stock

California Resources

Crescent Energy Company Class A Common Stock

Crescent Energy

Dorchester Minerals, L.P. - Common Units Representing Limited Partnership Interests

Dorchester Minerals

Gulfport Energy Corporation Common Shares

Gulfport Energy

Granite Ridge Resources, Inc. Common Stock

Granite Ridge Resources

HighPeak Energy

Kosmos Energy

Kimbell Royalty Partners Common Units Representing Limited Partner Interests

Kimbell Royalty Partners

Magnolia Oil & Gas Corporation Class A Common Stock

Magnolia Oil & Gas

Mach Natural Resources LP Common Units representing Limited Partner Interests

Mach Natural Resources

Matador Resources

Murphy Oil

Northern Oil & Gas

Sabine Royalty

SM Energy

Sitio Royalties Corp. Class A Common Stock

Sitio Royalties

Talos Energy

TXO Partners, L.P. Common Units Representing Limited Partner Interests

TXO Partners

Vista Energy S.A.B. de C.V. American Depositary Shares, each representing one series A share, with no par value

Comments

Sable Offshore

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL